Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes

International Journal of Clinical Practice

Volumn 60, Issue 3, 2006, Pages 275-283

  Dettmar, Peter W ^a,b   Sykes, J ^a   Little, S L ^a   Bryan, J ^a  

^a RECKITT BENCKISER   (United Kingdom)

^b Technostics Limited   (United Kingdom)

Author keywords

GORD; H2 receptor antagonists; Oesophageal pH; Proton pump inhibitors; Reflux suppressants; Reflux symptoms

Indexed keywords

ALGINIC ACID; LIQUID GAVISCON; OMEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH FUNDUS; STOMACH PH; SYMPTOM; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADOLESCENT; ADULT; AGED; ALGINATES; ANTACIDS; CROSS-OVER STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; RANITIDINE; TREATMENT OUTCOME;

EID: 33644782728     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00800.x     Document Type: Article

References (19)

1. Fass R, Sampliner RE, Mackel C et al. Age- and gender-related differences in 24-hour esophageal pH monitoring of normal subjects. Dig Dis Sci 1993; 38: 1926-8.
2. Csendes A, Rencoret G, Beltran M et al. Relationship between gastroesophageal reflux symptoms and 24 h esophageal pH measurement in patients with normal or minimally abnormal upper endoscopies. Rev Med Chil 2004; 132: 19-25.
3. Koufman JA, Belafsky PC, Bach KK et al. Prevalence of esophagitis in patients with pH-documented laryngopharyngeal reflux. Laryngoscope 2002; 112: 1606-9.
4. Csendes A, Smok G, Alvarez F et al. Patients with pathologic gastroesophageal reflux without erosive esophagitis: Correlation of the endoscopic and histological aspect of the esophagus. Rev Med Chil 1994; 122: 159-63.
5. Joelsson B, Johnsson F. Heartburn - the acid test. Gut 1989; 30: 1523-5.
6. Galmiche JP, Bruley des Varannes S. Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 62-8.
7. Rossett NE, Rice ML. An in-vitro evaluation of the efficacy of more frequently used antacids with particular attention to tablets. Gastroenterology 1954; 26: 490-5.
8. National Institute for Clinical Excellence. Guidance on the Use of Proton Pump Inhibitors (PPIs) in the Treatment of Dyspepsia. 12 July 2000.
9. May HA, Wilson CG, Hardy JG. Monitoring radiolabelled antacid preparations in the stomach. Int J Pharm 1984; 19: 169-76.
10. Washington N, Washington C, Wilson CG. Gastric distribution and residence time of two anti-reflux formulations. Int J Pharm 1987; 39: 163-71.
11. Washington N, Steele RJ, Jackson SJ et al. Patterns of food and acid reflux in patients with low-grade oesophagitis - the role of an anti-reflux agent. Aliment Pharmacol Ther 1998; 12: 53-8.
12. Washington N, Washington C, Wilson CG, Davis SS. The effect of inclusion of aluminium hydroxide in alginate-containing raft-forming antacids. Int J Pharm 1986; 28: 139-43.
13. Bennett CE, Hardy JG, Wilson CG The influence of posture on gastric emptying of antacids. Int J Pharm 1984; 21: 341-347.
14. Washington N, Spensley PJ, Smith CA et al. Dual pH probe monitoring versus single pH probe monitoring in infants on milk feeds: The impact on diagnosis. Arch Dis Child 1999; 81: 309-12.
15. Washington N, Wilson CG, Williams DL, Robertson C. An investigation into the effect of cimetidine pretreatment on raft formation of an anti-reflux agent. Aliment Pharmacol Ther 1996; 7: 553-9.
16. Washington N, Wilson CG, Davis SS. Evaluation of 'raft-forming' antacid neutralising capacity: In vitro and in vivo correlations. Int J Pharm 1985; 27: 279-86.
17. Fletcher J, Wirz A, Young J et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-83.
18. Burkitt V, Jolliffe IG, Sykes J, Dettmar PW. UK alginate suspensions - methodologies for investigating barrier properties. OESO 2000, 27.
19. Washington N. Investigation into the barrier action of an alginate gastric reflux suppressant, Liquid Gaviscon. Drug Invest 1990; 2: 23-30.